ClinicalTrials.gg
Not yet recruitingNCT07660172VAYHIT-PUpdated Jun 25, 2026

A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids.

A Phase 2 interventional study of Ianalumab and Eltrombopag in Primary Immune Thrombocytopenia (ITP), sponsored by Novartis Pharmaceuticals. Not yet recruiting. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
5 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic — 7 open to participants now, 7 under way, none of them phase 3. eltrombopag · Purpura, Thrombocytopenic, Idiopathic.

Planned enrollment
20th of 36
36 · median 40
Started
2027
the only one that year
Phase 2
15 of 36
2 open now
Registered
35th of 36
by date
Lead sponsor
6 of 36
Novartis Pharmaceuticals

Among the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, this one is the 20th largest by planned enrollment, is the only one that started in 2027, is one of 15 in phase 2, and was the 35th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

7 of the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About eltrombopag

eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 5 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy, safety and pharmacokinetics (PK) of ianalumab (VAY736) in addition to eltrombopag treatment; and to inform the dose of ianalumab in pediatric patients (5 to \<18 years of age) with primary ITP who have had an insufficient response to or relapsed after first-line treatment with corticosteroids.

Read the detailed description

The study will consist of 3 phases:

  • Screening phase
  • Treatment phase
  • Follow-up phase consisting of Efficacy follow-up phase and Safety follow-up phase
03

Conditions studied

  • Primary Immune Thrombocytopenia (ITP)

Keywords

  • Primary Immune Thrombocytopenia
  • ITP
  • VAY736
  • ianalumab
  • first-line corticosteroid treatment
  • eltrombopag
  • Pediatric patients
04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and/or assent must be obtained from the participant and/or their parent(s)/legal guardian(s) before any study-related activity or assessment is performed. Informed consent must be obtained from participants once they reach the local legal age of adulthood during the study.
  • Male or female patients aged 5 to \<18 years on the day of signing informed assent/consent (as appropriate for age).
  • A confirmed diagnosis of primary ITP, with insufficient response to, or relapse after a firstline therapy with or without IVIG.
  • Patients with count \<30 G/L for whom eltrombopag is clinically indicated (per physician's discretion) and with no to receive eltrombopag.
  • Patients who are up-to-date on childhood vaccinations as per the local recommended vaccination schedule.

Exclusion criteria

Exclusion Criteria:

  • Patients with ITP who received previous ITP treatments (other than therapy with or without IVIG) including splenectomy. However, patients exposed to thrombopoietin receptor agonists (TPO-RAs) for a limited time (maximum one week) before or during screening are eligible.
  • Patients with key renal or hepatic laboratory abnormalities.
  • Patients with other hematologic diagnosis associated with cytopenias, including Evans Syndrome.
  • Patients with current or history of life-threatening bleeding due to thrombocytopenia.
  • Patients who are (HIV), virus (HCV), surface antigen (HBsAg), or hepatitis B core antibody (HBcAb) positive.
  • Patients with known active or uncontrolled infections requiring systemic treatment during the screening period or history of recurrent infection.
  • Patients with hepatic impairment ( score >5, or equivalent).
  • Patients with concurrent bleeding disorders or coagulation disorders and/or receiving antiplatelet or anticoagulant medication.
  • Female patients who are nursing or pregnant.

Other protocol-defined inclusion/exclusion may apply.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Ianalumab + eltrombopag

    Participants will receive ianalumab in addition to eltrombopag.

    Biological: Ianalumab · Drug: Eltrombopag

Interventions

  • BiologicalIanalumab

    Liquid in a vial Concentrate for solution for infusion

    Also known as: VAY736

  • Film-coated tablet and also Powder for oral suspension

    Also known as: ETB115

06

What researchers measure

Primary outcomes

  1. Time to treatment failure (TTF)

    TTF is defined as the time from start of treatment until any of a list of specific events is met.

    Time frame: enrolled until end of study (up to 39 months from the last patient enrolled)

Secondary outcomes

  1. Stable response rate at 6 months (SR-6)

    SR-6 is defined as the percentage of participants with a platelet count of at least 50 G/L at 75% of the measures taken between Study Day 121 and 183, in the absence of rescue or new Immune Thrombocytopenia (ITP) therapy.

    Time frame: 6 months

  2. Stable response rate at 12 months (SR-12)

    SR-12 is defined as the percentage of participants with a platelet count of at least 50 G/L at 66% of the measures taken between Study Day 296 and 379, in the absence of rescue or new ITP therapy.

    Time frame: 12 months

  3. Complete Response (CR) rate

    CR is defined as the percentage of participants with any platelet count of at least 100 G/L in the absence of rescue treatment or new ITP treatment.

    Time frame: from enrollment until end of study (up to 39 months from the last patient enrolled)

  4. Response Rate (RR)

    RR is defined as the percentage of participants with any platelet count of at least 50 G/L in the absence of rescue treatment or new ITP treatment.

    Time frame: from enrollment until end of study (up to 39 months from the last patient enrolled)

  5. Time to response

    Time to response is defined as the time from the start of treatment to the date of the first response.

    Time frame: from enrollment until end of study (up to 39 months from the last patient enrolled)

  6. Time to complete response

    Time to complete response is defined as the time from the start of treatment to the date of complete response.

    Time frame: from enrollment until end of study (up to 39 months from the last patient enrolled)

  7. Duration of response

    Duration of response is defined as the time from achievement of response (platelet count ≥ 50 G/L) to treatment failure.

    Time frame: from enrollment until end of study (up to 39 months from the last patient enrolled)

  8. Duration of complete response

    Duration of complete response is defined as the time from achievement of response to loss of complete response.

    Time frame: from enrollment until end of study (up to 39 months from the last patient enrolled)

  9. Bleeding Events

    Percentage of participants with bleeding events according to WHO Bleeding Scale

    Time frame: from enrollment until end of study (up to 39 months from the last patient enrolled)

  10. Rescue medication

    Number and percentage of participants receiving rescue treatment

    Time frame: from enrollment until end of study (up to 39 months from the last patient enrolled)

  11. Rate of participants who successfully taper and discontinue eltrombopag - being treatment failure-free

    Treatment failure-free (as defined for the primary efficacy endpoint) at the end of the planned Treatment period.

    Time frame: End of Week 24

  12. Ianalumab serum concentration (Cmax)

    Cmax is the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body.

    Time frame: at pre-dose of each of the 4 dosing events and end-of-infusion and first and last dose

  13. B cell levels: Change from baseline in the frequency (% within CD45+ cells) and absolute number of CD19+ B cells

    Number and percentage of B-cell levels in the blood, and comparison with baseline levels of B-cells at specific timepoints.

    Time frame: 12 months after the first treatment of the last enrolled participant, final dbl: until end of study (up to 39 months from the last patient enrolled)

  14. B cell levels: Time to first occurrence of B cell recovery

    Time to first occurrence of B cell recovery is defined as ≥80% of baseline or ≥50 cells/μL.

    Time frame: 12 months after the first treatment of the last enrolled participant, final dbl: until end of study (up to 39 months from the last patient enrolled)

  15. Immunoglobulins: Change from baseline in immunoglobulin levels

    Change from baseline levels of serum immunoglobulins at specific timepoints.

    Time frame: 12 months after the first treatment of the last enrolled participant, final dbl: until end of study (up to 39 months from the last patient enrolled)

  16. Platelet counts: Change from baseline in platelet count

    Change from baseline levels of platelets at specific timepoints.

    Time frame: 12 months after the first treatment of the last enrolled participant, final dbl: until end of study (up to 39 months from the last patient enrolled)

  17. Incidence and titer of anti-ianalumab antibodies in serum (anti-drug-antibody (ADA) assay)

    Anti-drug antibodies (ADAs) are immune responses developed by a participant's body against biologic or gene therapies.

    Time frame: over time (up to 39 months from the last patient enrolled)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Data sharing details ↗ · www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2027; primary completion for Apr 2033, 74 months later.

Of 66 phase 2 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's planned 74 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2026
First posted
Jun 22, 2026
StartEst.
Feb 8, 2027
Primary completionEst.
Apr 22, 2033
CompletionEst.
Apr 22, 2033
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07660172
Responsible party
Sponsor
First posted
Jun 22, 2026
Start date
Feb 8, 2027 (estimated)
Primary completion
Apr 22, 2033 (estimated)
Completion
Apr 22, 2033 (estimated)
Last update
Jun 25, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
1-888-669-6682
Novartis Pharmaceuticals
Contact
+41613241111
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ianalumab · Eltrombopag

Start the discussion